Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, et al.
Journal for ImmunoTherapy of Cancer (2017) Vol. 5, Iss. 1
Open Access | Times Cited: 75

Showing 1-25 of 75 citing articles:

A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging
Leeat Keren, Marc Bossé, Diana M. Marquez, et al.
Cell (2018) Vol. 174, Iss. 6, pp. 1373-1387.e19
Open Access | Times Cited: 902
Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response
Tong‐Ming Fu, Lei-Jie Dai, Song‐Yang Wu, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 322
Mass Cytometry Imaging for the Study of Human Diseases—Applications and Data Analysis Strategies
Heeva Baharlou, Nicolas Canete, Anthony L. Cunningham, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 169
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma
Guangyu Ding, Jiaqiang Ma, Jing‐Ping Yun, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 3, pp. 608-618
Closed Access | Times Cited: 144
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Remy Thomas, Ghaneya Al‐Khadairi, Julie Decock
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 130
Reprogramming tumor-associated macrophages as a unique approach to target tumor immunotherapy
Safir Ullah Khan, Munir Ullah Khan, Muhammad Azhar Ud Din, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 55
The prognostic significance of peritumoral tertiary lymphoid structures in breast cancer
Michael Sofopoulos, Sotirios P. Fortis, Christoforos Vaxevanis, et al.
Cancer Immunology Immunotherapy (2019) Vol. 68, Iss. 11, pp. 1733-1745
Closed Access | Times Cited: 122
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies
Constantin N. Baxevanis, Sotirios P. Fortis, Sonia A. Perez
Seminars in Cancer Biology (2019) Vol. 72, pp. 76-89
Closed Access | Times Cited: 118
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
Keith E. Steele, Tze Heng Tan, R Korn, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 90
Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives
Umar Mehraj, Hina Qayoom, Manzoor Ahmad Mir
Breast Cancer (2021) Vol. 28, Iss. 3, pp. 539-555
Closed Access | Times Cited: 70
DNA methylation-based signature of CD8+ tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer
Qi Zou, Xiaolin Wang, Donglin Ren, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 9, pp. e002671-e002671
Open Access | Times Cited: 59
Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model
Álvaro Ruiz-Martínez, Chang Gong, Hanwen Wang, et al.
PLoS Computational Biology (2022) Vol. 18, Iss. 7, pp. e1010254-e1010254
Open Access | Times Cited: 46
Prognostic value of CD163+ macrophages in solid tumor malignancies: A scoping review
Henriette Mathiesen, Kristian Juul‐Madsen, Trine Tramm, et al.
Immunology Letters (2025), pp. 106970-106970
Open Access | Times Cited: 1
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence
Tommy A. Brown, Elizabeth A. Mittendorf, Diane F. Hale, et al.
Breast Cancer Research and Treatment (2020) Vol. 181, Iss. 2, pp. 391-401
Open Access | Times Cited: 62
Targeting Tumor-Associated Macrophages in Anti-Cancer Therapies: Convincing the Traitors to Do the Right Thing
Cristina Belgiovine, Elisabeth Digifico, Clément Anfray, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 10, pp. 3226-3226
Open Access | Times Cited: 62
Predictive and Prognostic Relevance of Tumor-Infiltrating Immune Cells: Tailoring Personalized Treatments against Different Cancer Types
Tikam Chand Dakal, Nancy George, Caiming Xu, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1626-1626
Open Access | Times Cited: 6
The role of immune infiltrates as prognostic biomarkers in patients with breast cancer
Constantin N. Baxevanis, Michael Sofopoulos, Sotirios P. Fortis, et al.
Cancer Immunology Immunotherapy (2019) Vol. 68, Iss. 10, pp. 1671-1680
Open Access | Times Cited: 49
CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment
Yanzhu Chen, Zhishang Meng, Lin Zhang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 41
Tumor-Associated Macrophages: Combination of Therapies, the Approach to Improve Cancer Treatment
Pedram Moeini, Paulina Niedźwiedzka‐Rystwej
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 7239-7239
Open Access | Times Cited: 36
PKHB1, a thrombospondin-1 peptide mimic, induces anti-tumor effect through immunogenic cell death induction in breast cancer cells
Kenny Misael Calvillo‐Rodríguez, Rodolfo Mendoza-Reveles, Luis Gómez‐Morales, et al.
OncoImmunology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 27
Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response
Bernardo L. Rapoport, Simon Nayler, Bernhard Mlecnik, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2525-2525
Open Access | Times Cited: 27
TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy
Pauline Hamon, Marine Gerbé de Thoré, Marion Classe, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 3, pp. e003519-e003519
Open Access | Times Cited: 23
Spatial Metrics of Interaction between CD163-Positive Macrophages and Cancer Cells and Progression-Free Survival in Chemo-Treated Breast Cancer
Brenton Maisel, Misung Yi, Amy R. Peck, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 308-308
Open Access | Times Cited: 20
Prognostic value of various immune cells and Immunoscore in triple-negative breast cancer
Xinyu Ren, Yu Song, Junyi Pang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Geospatial characterization of immune cell distributions and dynamics across the microenvironment in clear cell renal cell carcinoma
Nicholas H. Chakiryan, Youngchul Kim, Anders Berglund, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 4, pp. e006195-e006195
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top